

Zoono Group Limited (ASX: ZNO)**ASX ANNOUNCEMENT**

18 May 2026

Upcoming Expiry of Unlisted Options

Zoono Group Limited (**Company**) (ASX: ZNO) advises that 7,201,598 unlisted options, exercisable at \$0.10 will expire at 5.00pm (AEST) on Tuesday, 2 June 2026. The options were issued to shareholders who participated in the 2023 pro-rata non-renounceable entitlement issue on the basis of one option for every three shares applied for.

Holders can exercise all or part of their options prior to the Expiry Date by providing the Company a completed notice of exercise of options form specifying the number of options being exercised and the required payment of funds. There is no obligation for option holders to exercise their options.

The market sale price of ordinary shares in Zoono on the ASX was \$0.068 on Friday, 15 May 2026, being the latest available market price of shares on ASX prior to this announcement.

During the three (3) months preceding the date of this notice:

- The highest market sale price of ordinary shares on the ASX was \$0.078 on 16 April 2026; and
- The lowest market sale price of ordinary shares on the ASX was \$0.054 on 27 March 2026.

The total number of Options on issue is 7,201,598.

On exercise, each Option entitles the holder to receive one fully paid ordinary share in the capital of the Company. If all of the Options on issue are exercised, 7,201,598 fully paid ordinary shares in the capital of the Company will be issued.

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited

For further information, please contact:**Zoono Group Limited**

Paul Hyslop
Group Managing Director
M: +64 21 659 977
E: paul.hyslop@zoono.com.

Paul Ravlich
Group CFO
M: +64 21 075 9176
E: paul.ravlich@zoono.com.

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ

protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com